glp-1 drugs key developments 2025 Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 2025’s Breakthrough GLP-1 Obesity Treatments:

The better medication depends on your specific goals, budget, and medical situation

However, a national Blue Health Intelligence study from the Blue Cross Blue Shield Association finds that more than 30% of patients dropped out of treatment after the first four weeks and 58% of patients taking the medications for weight loss discontinued use before seeing a clinical benefit

It is not licensed for general prescribing

The trial, extended for 2 years, found that completers maintained a 7.8 kg weight loss from baseline [15]

Open questions The authors cautioned that the trial was a small pilot study and not randomized, adding that all participants had obesity